key: cord-1024479-opjs1nj2 authors: Gabet, Amélie; Grave, Clémence; Tuppin, Philippe; Chatignoux, Edouard; Béjot, Yannick; Olié, Valérie title: Impact of the COVID‐19 pandemic and a national lockdown on hospitalizations for stroke and related 30‐day mortality in France: A nationwide observational study date: 2021-03-29 journal: Eur J Neurol DOI: 10.1111/ene.14831 sha: 097fbcd10d69173551872619774a832797eb8d65 doc_id: 1024479 cord_uid: opjs1nj2 BACKGROUND AND PURPOSE: The aim of this nationwide study was to assess the impact of the COVID‐19 pandemic on stroke hospitalization rates, patient characteristics and 30‐day case fatality rates. METHODS: All hospitalizations for stroke from January to June of each year from 2017 to 2020 were selected using International Classification of Diseases, 10th revision, codes I60 to I64 in the national hospital discharge database. Patient characteristics and management were described according to three time periods: pre‐lockdown, lockdown, and post‐lockdown. Weekly incidence rate ratios (IRRs) were computed to compare time trends in the rates of patients hospitalized for stroke as well as in‐hospital and 30‐day case fatality rates between the years 2017–2019 and 2020. RESULTS: In 2020, between weeks 1 and 24, 55,308 patients were hospitalized for stroke in France. IRRs decreased by up to 30% for all age groups, sex, and stroke types during the lockdown compared to the period 2017–2019. Patients hospitalized during the second and third weeks of the lockdown had higher in‐hospital case fatality rates compared to 2017–2019. In‐hospital case fatality rates increased by almost 60% in patients aged under 65 years. Out‐of‐hospital 30‐day case fatality rates increased between weeks 11 and 15 among patients who returned home after their hospitalization. Important changes in care management were found, including fewer stroke patients admitted to resuscitation units, more admitted to stroke care units, and a shorter mean length of hospitalization. CONCLUSIONS: During the first weeks of the lockdown, rates of patients hospitalized for stroke fell by 30% and there were substantial increases of both in‐hospital and out‐of‐hospital 30‐day case fatality rates. hospitalized for stroke during the COVID-19 pandemic have been described in local areas of France as well as in other countries [1, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . However, the magnitude of this decrease differed among countries, with only a limited decline in stroke admissions in Germany [15] compared with a 39% reduction in the United States [3, 4] and a 60% reduction in the Veneto region of Italy [12, 16] . By contrast, a study conducted in Brescia, Italy, reported similar rates of stroke admissions and even a higher rate of ischemic stroke admissions during the months of March and April 2020 compared to previous years [17] . The authors hypothesized that the SARS-CoV-2 infection might be associated with a higher risk of ischemic events [17] . Few studies, however, have explored the impact of the COVID-19 pandemic on stroke hospitalization at a whole-country level in Europe or North America (Table S1 ). As stroke is an emergency condition that requires quick and specific care and represents one of the main causes of disability and death in many countries [18] , the impact of the pandemic on this acute disease is a major public health concern. The first objective of this study was to evaluate the collateral effects of the COVID-19 pandemic on stroke epidemiology, including hospitalizations and outcomes. The secondary objective was to evaluate the impact of the pandemic on stroke care organization and stroke management. Thus, this nationwide study compares the rates of patients hospitalized for stroke in France in the weeks before, during, and after the lockdown in 2020 with the corresponding weeks in the years 2017 to 2019. The study describes changes in patient characteristics and care management during lockdown and analyses the time trends of in-hospital and 30-day out-of-hospital case fatality rates. For this observational and cross-sectional study, we used data from the national hospital discharge database (Programme de médicalisation des systèmes d'information [PMSI] ), which comprehensively collects all stays in both private and public hospitals across France, covering a population of approximately 66 million inhabitants [19] . Data collected in the PMSI are linked to the French national health database (Système National des Données de Santé [SNDS] ), which comprehensively gathers individual outpatient data such as healthcare prescriptions and procedures reimbursed by the French national health insurance system for all individuals living in France and covered by universal medical coverage. The SNDS also records the long-term disease status of patients, which entitles them to 100% reimbursement for all healthcare expenditures related to that particular disease [19] . All patients hospitalized for stroke between weeks 1 and 24 from 2017 to 2020 were selected. After week 24, an exhaustive record of hospitalizations could not be ensured. Stroke was defined by codes I60 to I64 of the International Classification of Diseases, 10th revision (ICD-10), which were registered as the main diagnosis of the entire hospital stay or one of the medical units where the patient stayed [20, 21] . For each patient, we selected the first hospitalization for stroke between weeks 1 and 24 of each year. The following patient characteristics were recorded for the hospital stay: age, sex, type of stroke (ischemic [ICD-10 codes I63 or I64] and haemorrhagic [I60 to I62]), obesity (E66), and stroke signs (speech impairment [R47] or paralysis [G81]). We also recorded an infection with SARS-CoV-2 identified with a positive PCR, antigenic or serologic test, or through computed tomography. The weekly number of patients hospitalized with a SARS-CoV-2 infection in France is presented in Figure S1 . Using medical data for the 5 years preceding the hospitalization for stroke, cardiovascular and non-cardiovascular comorbidities were recorded. We then calculated a Charlson index score of comorbidities [22] , which included congestive heart failure, dementia, chronic pulmonary disease, rheumatologic disease, mild liver disease, diabetes with chronic complications, hemiplegia or paraplegia, renal disease, any malignancy (including leukemia and lymphoma), moderate or severe liver disease, metastatic solid tumor, and AIDS/HIV. Three groups were defined according to the number of comorbidities: scores from 0 to 1, from 2 to 3, and 4 or more. The underlined hypothesis of such analysis was the modification of stroke care access during the COVID-19 pandemic according to the level of comorbidities. Lastly, treatments given for cardiovascular conditions or their risk factors were considered if the patients had at least three drug deliveries in the year preceding the hospitalization for stroke. Several aspects of acute care management were considered. We focused on patients' admission to a resuscitation unit or a stroke care unit. In France, intensive care units are intended to treat visceral failures related to a single organ specialty. In the case of multi-visceral failure, patients must be transferred to a resuscitation unit which is equipped with invasive ventilation. A severity score was completed by the physicians for patients admitted to a resuscitation unit. This score corresponds to the simplified acute physiology score (SAPSII) [23] . Regarding acute stroke treatment, data on mechanical thrombectomy (MT) were available exhaustively from 2017 onwards, whereas intravenous thrombolysis (IVT) was not. The length of hospital stay was calculated based on the number of nights spent in hospital. At discharge, we collected information about whether the patient returned home, was transferred to another medical unit (i.e., a short-stay medical unit, follow-up and rehabilitation care) or elsewhere (i.e., long-stay facilities, nursing home, or hospitalized at home), or died in hospital. At discharge, % In line with the French governmental regulations and the National Ethics Committee, no patient consent was required. The databases used in the study contained pseudonymized patient information. In 2020, between weeks 1 and 24, 55,308 patients were hospitalized for stroke in France (Table 1) (Table 1 ). In patients admitted to resuscitation units, the mean SAPSII declined from week 12 onwards ( Figure S5 ). The same observation was made after excluding stroke patients who died (data not shown). Regarding comorbidities, no significant change in the proportion of patients with a Charlson index score ≥2 was observed in the weekly analysis ( Figure 3 ). However, a higher proportion of patients presenting speech impairment or paralysis was found in weeks [9] [10] [11] [12] [13] in 2020 compared to 2017-2019 ( Figure 3 ). The increase in the proportion of patients with these symptoms reached 10% in week 13. The weekly ORs for MT increased significantly over the weeks of the lockdown ( Figure S6 ). In-hospital case fatality rates increased by 30% at the beginning of the lockdown in France compared to previous years ( Figure 4 ). This observation occurred in all age groups and types of stroke, although a greater increase in in-hospital case fatality rates (approximately 60%) was found in stroke patients aged under 65 years ( Figure S7 ). were 15% more likely to have atrial fibrillation in 2020 compared to 2017-2019 ( Figure S8 ). In weeks 11-15, an increase in 30-day case fatality rates after hospital admission was also observed among patients affiliated to the general health insurance scheme who returned home at the end of their hospitalization for stroke ( Figure 4 ). All the results remained unchanged when excluding stroke patients with a history of stroke or those infected by SARS-CoV-2. To the best of our knowledge, this is the first study to investigate the According to our findings, the decrease in hospitalization rates for stroke started 2 weeks before the beginning of the lockdown in (Table S1 ). In a Danish nationwide study, stroke admissions rates after the lockdown returned to similar levels during the time period prior to the COVID-19 pandemic [7] . Although we observed similar declines in patients hospitalized for both ischemic and haemorrhagic strokes, the Danish study showed different time trends according to the type of stroke, with no decline in admissions for haemorrhagic strokes [7] , which are more severe than ischemic strokes. In our study, however, the lower hospitalization rates in 2020 compared to 2017-2019 also impacted the most severe strokes. A similar decrease in hospitalization for TIA was also observed, which raises concerns about the possible increase in related strokes in the future. The decline in hospitalization rates for stroke might have been attributable to patients' fear of being infected with SARS-CoV-2, causing them not to seek medical attention. A decline in stroke triggers such as stress and air pollution during the lockdown might also partly explain the decline in hospitalization rates for stroke [24, 25] . Finally, the lower incidence of stroke hospitalizations might be explained by the high mortality of the SARS-CoV-2 infection, mechanically reducing the number of inhabitants at risk of stroke. In England and Wales, cerebrovascular mortality rates declined by 18% in March 2020 compared to the previous years [26] . We found greater in-hospital case fatality rates during the first weeks of the lockdown in France and higher out-of-hospital 30day case fatality rates after hospital admission in the subpopulation of patients affiliated to the general health insurance scheme. Several studies have reported higher mortality rates in stroke patients hospitalized during the pandemic [17, 27] ; however, no study to date has shown such an increase in in-hospital case fatality rates in stroke patients aged under 65 years (Table S1) higher in-hospital case fatality rates. In line with this observation, several studies have shown an increase in severity scores [8] or in the proportion of severe strokes during the lockdown [28] . A study from the United States showed a rise in the proportion of large vessel occlusion strokes during the COVID-19 pandemic, thus highlighting higher rates of severe stroke [8] . We found a significant increase in the probability of atrial fibrillation in patients hospitalized for ischemic stroke during week 13, the second week of the lockdown. This could reflect the higher rates of cardioembolic strokes, which are generally more severe types of stroke. Moreover, a nationwide Danish study demonstrated a trend towards an increase in ischemic strokes related to atrial fibrillation following the lockdown [29] . The rise in the proportion of patients with speech impairment or paralysis that we observed is consistent with the assumption of higher rates of patients hospitalized for severe stroke during the first weeks of the lockdown in France. Lower rates of MT, however, were found in our study in 2020 compared to 2019, as previously described in a national multicentre study in France [30] . We observed an increase in the proportion of patients with ischemic strokes who benefitted from this treatment during the lockdown. As mentioned above, this could be attribut- Our study provides an exhaustive report on stroke hospitalizations during the COVID-19 pandemic in France for the period before, during and after the lockdown, and compares these data to the same time periods in 2017-2019. Nevertheless, several limitations should be highlighted. We were unable to include certain stroke characteristics such as the formal evaluation of severity using a dedicated scale or the mechanisms of ischemic stroke, thus limiting the interpretation of the results regarding the severity of stroke patients during the COVID-19 pandemic and the higher inhospital case fatality rates during this period. However, our study included in-hospital case fatality rates and 30-day mortality, two major outcomes directly linked to stroke severity. In addition, several aspects relating to care management were not available, such as the time between the onset of stroke symptoms and hospital admission, while others were not fully available, such as IVT. Caution should be taken in the interpretation of results based on one single week. In conclusion, this nationwide study shows the substantial im- pandemic to minimize the delay between the onset of stroke symptoms and the admission to hospital. The French stroke care network generally seemed to have effectively handled the first wave of the crisis, although further analyses are required to assess any regional variations in greater detail and to evaluate the cause of death data in France in order to estimate the possible out-of-hospital excess deaths related to stroke. Prolonged surveillance of hospitalization for stroke will be needed to analyse the mid-term impact of the COVID-19 pandemic and the lockdown on stroke patients in France. None. There is no conflict of interest with the present work. Validation (lead) Visualization (lead) Writing -original draft (lead) Clémence Grave: Conceptualization (equal) Data curation (equal); Formal analysis (equal) Validation (equal) Visualization (equal) Edouard Chatignoux: Conceptualization (equal) Data curation (equal); Formal analysis (equal) Validation (equal) Visualization (supporting) Philippe Tuppin: Conceptualization (equal) Investigation (lead) Supervision (lead) Validation (equal) Visualization (lead) Yannick Bejot: Conceptualization (equal) Investigation (lead) Supervision (equal) Validation (lead) Visualization (equal) Valérie Olié: Conceptualization (lead); Funding acquisition Supervision (lead) Validation (lead) Writing -review and editing (lead) Stroke care during the COVID-19 pandemic: experience from three large European countries Excess all-cause mortality during the first wave of the COVID-19 epidemic in France Collateral effect of Covid-19 on stroke evaluation in the United States The impact of COVID-19 on acute ischemic stroke admissions: analysis from a community-based tertiary care center Decline in stroke alerts and hospitalisations during the COVID-19 pandemic Break in the stroke chain of survival due to COVID-19 Effect of COVID-19 on firsttime acute stroke and transient ischemic attack admission rates and prognosis in Denmark: a nationwide cohort study Falling stroke rates during COVID-19 pandemic at a comprehensive stroke center Stroke code presentations, interventions, and outcomes before and during the COVID-19 pandemic Impact of the COVID-19 outbreak on acute stroke care The effect of COVID-19 on stroke hospitalizations in New York City Stroke care in Italy: an overview of strategies to manage acute stroke in COVID-19 time Reduced admissions for cerebrovascular events during COVID-19 outbreak in Italy The Impact Of The COVID-19 Pandemic On Hospital Admissions In The United States. Health Affairs Temporal trends in the presentation of cardiovascular and cerebrovascular emergencies during the COVID-19 pandemic in Germany: an analysis of health insurance claims Acute stroke management pathway during Coronavirus-19 pandemic Effects of COVID-19 outbreak on stroke Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study Value of a national administrative database to guide public decisions: From the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France How accurate is the reporting of stroke in hospital discharge data? A pilot validation study using a population-based stroke registry as control Positive predictive value of french hospitalization discharge codes for stroke and transient ischemic attack Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study Air pollution and stroke. A new modifiable risk factor is in the air What is happening to non-covid deaths? Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry Impact of COVID-19 outbreak in reperfusion therapies of acute ischaemic stroke in northwest Spain New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people Mechanical thrombectomy for acute ischemic stroke amid the COVID-19 outbreak Effect of the COVID-19 pandemic on acute stroke reperfusion therapy: data from the Lyon Stroke Center Network Impact of the COVID-19 outbreak on acute stroke pathways -insights from the Alsace region in France In-hospital delays for acute stroke treatment delivery during the COVID-19 pandemic Impact of the COVID-19 pandemic and a national lockdown on hospitalizations for stroke and related 30-day mortality in France: A nationwide observational study Full access to the SNDS is granted to Santé Publique France by decree. https://orcid.org/0000-0003-1273-8988